# Tuspetinib

Source: https://onco.cc/drugs/tuspetinib/  
OnCo record `tuspetinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tuspetinib is an oral kinase inhibitor from Aptose Biosciences Inc., in registered phase 2 trials for myelodysplastic syndromes / neoplasms, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms.

## Summary

Tuspetinib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Aptose Biosciences Inc., in myelodysplastic syndromes / neoplasms, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms. A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Also known as: HM43239
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Oral kinase inhibitor
- Mechanism: A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below.

## Sources

- ClinicalTrials.gov: trials of Tuspetinib: https://clinicaltrials.gov/search?intr=Tuspetinib

## Connected records

- cancers: [Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms](https://onco.cc/cancers/cmml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- companies: [Aptose Biosciences](https://onco.cc/companies/aptose/)
- trials: [Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia](https://onco.cc/trials/nct03850574/)

---
JSON: https://onco.cc/api/v1/entities/tuspetinib.json